Calcibind Disease Interactions
There are 3 disease interactions with Calcibind (cellulose sodium phosphate).
Cellulose sodium phosphate (applies to Calcibind) bone disease
Major Potential Hazard, High plausibility. Applicable conditions: Hyperparathyroidism, Osteoporosis, Malabsorption Syndrome
The use of cellulose sodium phosphate is contraindicated in patients with hyperparathyroidism (primary or secondary), bone disease (osteomalacia, osteoporosis), or low intestinal absorption and renal excretion of calcium. Cellulose sodium phosphate prevents absorption of intestinal calcium and can further increase the risk of calcium adsorption and bone disease.
Cellulose sodium phosphate (applies to Calcibind) electrolyte imbalance
Major Potential Hazard, High plausibility. Applicable conditions: Nephrolithiasis, Malabsorption Syndrome, Hypocalcemia, Magnesium Imbalance, Phosphate Imbalance
The use of cellulose sodium phosphate is contraindicated in patients with undiagnosed hypophosphatemia (possible renal dysfunction or hypoparathyroidism), hypocalcemia (possible hypoparathyroidism, malabsorption syndrome), hypomagnesemia (further decrease may result in seizures), or hyperoxaluria (increased risk of renal oxalate stones).
Sodium salts (applies to Calcibind) sodium/water imbalance
Major Potential Hazard, High plausibility. Applicable conditions: Hyponatremia, Hypokalemia, Congestive Heart Failure, Fluid Retention
Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.
Calcibind drug interactions
There are 2 drug interactions with Calcibind (cellulose sodium phosphate).
More about Calcibind (cellulose sodium phosphate)
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.